Recombinant HIV-1 Envelope Proteins and Their Use

Millions of people are infected with HIV-1 worldwide. In the U.S., there are about 30,000 new cases of HIV infection reported annually. Currently, there are effective, anti-retroviral therapeutics available to treat or prevent HIV infection. However, available anti-retroviral therapeutics require life-long administration.

During infection, proteases of the host cell cleave gp160 into gp120 and gp41. Gp41 is an integral membrane protein, while gp120 protrudes from the mature virus. Together gp120 and gp41 aggregate as trimers that make up the HIV-1 envelope (“Env”) spike, which is a target for neutralizing antibodies.

NIAID researchers have constructed a recombinant HIV-1 trimer immunogen. In particular, the recombinant gp120 protein in the trimer is stabilized in a closed conformation, preventing it from binding to CD4. The advantage of the closed conformation is that it can stabilize the epitopes that bind to broadly neutralizing antibodies, minimize the binding of gp120 with weakly or non-neutralizing antibodies, and prevent conformational changes induced by CD4 as well as immunogen sequestration by CD4in vivo. Research has also indicated that recombinant Env ectodomain trimers can induce higher neutralizing antibody titers than wild type Env trimers in animal models.

This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as well as for further development and evaluation under a research collaboration.

Potential Commercial Applications: Competitive Advantages:
  • HIV-1 immunogen
  • New methods for isolating broadly neutralizing antibodies
  • A new strategy in inducing immune response against HIV-1


Paolo Lusso (NIAID)  ➽ more inventions...

Peng Zhang (NIAID)  ➽ more inventions...

Intellectual Property:
US Application No. 62/306,006
PCT Application No. PCT/US2017/021573

Huang J., et al. PMID: 25186731

Collaboration Opportunity:

The Technology Transfer and Intellectual Property Office (TTIPO) is seeking parties interested in collaborative research to further develop the technology. In particular, NIAID is interested in partnerships utilizing vector vaccine platforms for expressing these immunogens. However, NIAID is willing to discuss other applications of this technology. For collaboration opportunities, please contact Chris Kornak at chris.kornak@nih.govor 1-240-627-3705.

Licensing Contact:
Christopher Kornak, J.D.
Phone: 240-627-3705

OTT Reference No: E-102-2016-0
Updated: Jun 27, 2018